Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Alliance Pharmaceutical Corp.' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Alliance Pharmaceutical Corp.' found in 1 term [] and 1 definition []
1 - 2 (of 2)     
Result Pages : [1]
MRI Resources 
MRI Training Courses - Corporations - Spectroscopy - Services and Supplies - Shoulder MRI - MRI Centers
 
Alliance Pharmaceutical Corp.MRI Resource Directory:
 - Manufacturers -
 
www.allp.htm California-based research and development company. Alliance has several patents regarding 'microbubble' compositions such as Imagent® that are intended to enhance ultrasound imaging and Imagent GI as a gastrointestinal MRI contrast agent. Another product is Oxygent™, a synthetic 'blood substitute'.

MRI Contrast Agents:
Contact Information
MAIL
Alliance Pharmaceutical Corp.
6175 Lusk Blvd.
San Diego, CA 92121
USA
PHONE
+1-858-410-5200
FAX
+1-858-410-5161
spacer
 
• Share the entry 'Alliance Pharmaceutical Corp.':  Facebook  Twitter  LinkedIn  
 
Further Reading:
  Basics:
Slumping MRI market prompts Alliance to halt GI contrast agent effort
Wednesday, 28 September 1994   by www.searchmedica.com    
MRI Resources 
Patient Information - Coils - Chemistry - Knee MRI - Hospitals - Spectroscopy
 
Imagent GIInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Perflubron® is a perfluorochemical for use as an oral contrast agent. Due to its insolubility in water it does not mix with intestinal secretions; thus bowel lumina appear homogeneously dark on MR images when Perflubron® replaces bowel contents. Filled bowel loops appear black with all pulse sequences because the contrast agent lacks mobile protons.
It is commercially available as Imagent GI. Because rapid transit through the gastrointestinal tract it reaches the rectum within 30 to 40 minutes in most patients. MR imaging of the upper abdominal region should begin within 15 minutes and of the pelvic region 15 to 60 minutes after ingestion of perflubron.

See also Classifications, Characteristics, etc.
Drug Information and Specification
NAME OF COMPOUND
Perfluoroctylbromide
DEVELOPER
CONTRAST EFFECT
Negative enhancement
Proton density reduction, signal void
PHARMACOKINETIC
Gastrointestinal
CONCENTRATION
Water immiscible liquid
DOSAGE
9 mL per kg of body weight
PREPARATION
Finished product
INDICATION
Bowel marking
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Bottle of 200cc
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
USA
Imagent GI®
For sale
spacer

• View the DATABASE results for 'Imagent GI' (3).Open this link in a new window

 
Further Reading:
  News & More:
Slumping MRI market prompts Alliance to halt GI contrast agent effort
Wednesday, 28 September 1994   by www.searchmedica.com    
MRI Resources 
Spectroscopy pool - Shielding - Cochlear Implant - Anatomy - Homepages - Absorption and Emission
 
     1 - 2 (of 2)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



Next big thing in MRI will be :
AI 
remote operator 
personalized protocols 
helium-free 
molecular MRI 
portable MRI 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 3 December 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]